Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

MYGN

M

Myriad Genetics, Inc. (MYGN)

NMS – Цена в реальном времени. Валюта: USD

4.28

-0.34 (-7.36%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

4.33

+0.05 (1.17%)

После закрытия: Mar 27, 2026, 7:41 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?

Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term

Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer

Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth despite modest revenue decline. MYGN's core franchises—Prolaris and hereditary cancer—showed resilience, offsetting reimbursement headwinds in mental health and weakness in prenatal testing. Cost-cutting drove sharply lower operating expenses and narrowed losses, while gross margins remained stable at 70%, signaling operational stabilization.

MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down

MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down

Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.

Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million. Full year 2025 revenue of $824.5 million decreased 2% year-over-year.

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the FirstGene ® Multiple Prenatal Screen in Clinical Chemistry. The study showed that each component of the test had exceptional sensitivity and specificity.

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance.